RDEA3170 and Allopurinol Combination Study in Gout Subjects
Status:
Completed
Trial end date:
2015-09-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male
subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics
(PD) of RDEA3170 or allopurinol alone and in combination in the fed state.